Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Lxh254
1. Lxh254
2. 1800398-38-2
3. Lxh-254
4. Lxh254 Free Base
5. N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide
6. Pan-raf Inhibitor Lxh254
7. Naporafenib [inn]
8. 15jl80dg6h
9. 1800398-38-2 (free Base)
10. N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide
11. 4-pyridinecarboxamide, N-(3-(2-(2-hydroxyethoxy)-6-(4-morpholinyl)-4-pyridinyl)-4-methylphenyl)-2-(trifluoromethyl)-)-
12. N-(3-(2-(hydroxyethoxy)-6-(morpholin-4-yl) Pyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)pyridine-4-carboxamide
13. N-{3-[2-(2-hydroxyethoxy)-6-(morpholin-4-yl)pyridin-4-yl]-4-methylphenyl}-2-(trifluoromethyl)pyridine-4-carboxamide
14. Lxh 254
15. K81
16. Unii-15jl80dg6h
17. Naporafenib [who-dd]
18. Chembl4583691
19. Lxh 254 [who-dd]
20. Schembl16094629
21. Bdbm88120
22. Gtpl10658
23. Bcp29080
24. Ex-a1846
25. Nsc807047
26. S8745
27. Akos037648965
28. At23218
29. Nsc-807047
30. Compound 15 [pmid: 31059256]
31. Ac-36207
32. Bl166445
33. Bs-16133
34. Hy-112089
35. Cs-0043317
36. Example 1156 [wo2014151616a1]
37. A16841
38. Us9694016, 1156
| Molecular Weight | 502.5 g/mol |
|---|---|
| Molecular Formula | C25H25F3N4O4 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Exact Mass | 502.18278978 g/mol |
| Monoisotopic Mass | 502.18278978 g/mol |
| Topological Polar Surface Area | 96.8 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 709 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Drugs in Development
Details:
ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2024
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Erasca Starts Phase 3 Trial for Naporafenib in Melanoma
Details : ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.
Product Name : ERAS-254
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2024
Details:
The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $184.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 21, 2024
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $184.0 million
Deal Type : Public Offering
Erasca Announces Closing of Underwritten Offering of Common Stock and Additional Shares
Details : The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.
Product Name : ERAS-254
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 21, 2024
Details:
Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: BofA Securities
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 27, 2024
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : BofA Securities
Deal Size : $45.0 million
Deal Type : Private Placement
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Details : Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.
Product Name : ERAS-254
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2024
Details:
The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 14, 2024
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Erasca Announces Clinical Trial Collaboration and Supply Agreements for Trametinib
Details : The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.
Product Name : ERAS-254
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 14, 2024
Details:
LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2023
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .
Product Name : ERAS-254
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Details:
ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2023
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.
Product Name : ERAS-254
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2023
Details:
LXH254 (naporafenib) is a potent and selective inhibitor of BRAF and CRAF, with a potential first-in-class and best-in-class profile. Erasca plans to focus on securing potential regulatory approval for naporafenib plus trametinib in RAS Q61X tissue agnostic solid tumors.
Lead Product(s): Naporafenib
Therapeutic Area: Oncology Brand Name: LXH254
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Erasca
Deal Size: $300.0 million Upfront Cash: $300.0 million
Deal Type: Licensing Agreement September 12, 2022
Lead Product(s) : Naporafenib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Erasca
Deal Size : $300.0 million
Deal Type : Licensing Agreement
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
Details : LXH254 (naporafenib) is a potent and selective inhibitor of BRAF and CRAF, with a potential first-in-class and best-in-class profile. Erasca plans to focus on securing potential regulatory approval for naporafenib plus trametinib in RAS Q61X tissue agnos...
Product Name : LXH254
Product Type : Other Small Molecule
Upfront Cash : $300.0 million
September 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
14
PharmaCompass offers a list of Naporafenib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naporafenib manufacturer or Naporafenib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naporafenib manufacturer or Naporafenib supplier.
PharmaCompass also assists you with knowing the Naporafenib API Price utilized in the formulation of products. Naporafenib API Price is not always fixed or binding as the Naporafenib Price is obtained through a variety of data sources. The Naporafenib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Naporafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naporafenib, including repackagers and relabelers. The FDA regulates Naporafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naporafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Naporafenib supplier is an individual or a company that provides Naporafenib active pharmaceutical ingredient (API) or Naporafenib finished formulations upon request. The Naporafenib suppliers may include Naporafenib API manufacturers, exporters, distributors and traders.
Naporafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Naporafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naporafenib GMP manufacturer or Naporafenib GMP API supplier for your needs.
A Naporafenib CoA (Certificate of Analysis) is a formal document that attests to Naporafenib's compliance with Naporafenib specifications and serves as a tool for batch-level quality control.
Naporafenib CoA mostly includes findings from lab analyses of a specific batch. For each Naporafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Naporafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Naporafenib EP), Naporafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naporafenib USP).
